---
title: "Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292530453.md"
description: "Sanuwave Health has announced their preliminary revenue for the second quarter of 2026 to range between $9.6 million and $9.8 million, surpassing the upper limit of their revised guidance."
datetime: "2026-07-13T20:32:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292530453.md)
  - [en](https://longbridge.com/en/news/292530453.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292530453.md)
generator: "portal-rs"
---

# Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

Sanuwave Health has announced their preliminary revenue for the second quarter of 2026 to range between $9.6 million and $9.8 million, surpassing the upper limit of their revised guidance.

### Related Stocks

- [SNWV.US](https://longbridge.com/en/quote/SNWV.US.md)

## Related News & Research

- [SANUWAVE Health Q2 revenue falls, withdraws FY guidance amid Medicare reimbursement uncertainty](https://longbridge.com/en/news/295144804.md)
- [SYNSAM: Double-digit sales and profit growth in Q2, with strong margins and expanding subscriptions](https://longbridge.com/en/news/296571574.md)
- [Lowe's Q2 sales slightly miss estimates; lowers FY guidance amid DIY weakness](https://longbridge.com/en/news/296337476.md)
- [Will Lowe's (LOW) Stock Rise or Fall After Q2 Earnings?](https://longbridge.com/en/news/296255676.md)
- [Lowe’s stock shrugs off weak guidance after a second-quarter earnings beat](https://longbridge.com/en/news/296374202.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**